Cheryl's CV

Cheryl F. Scott

is really

Cheryl Faye Schwartz

Cheryl's Index

Cheryl and Computers

Cheryl and Herbal Medicine

Cheryl's History

Cheryl and BenSalem Naturals

Cheryl and Astrology

Cheryl's Fibromyalgia Web

CURRICULUM VITAE

(nee Cheryl Faye Schwartz)

FORMER OFFICE ADDRESS:

(12-1-78 to 8-27-99)

located in

3400 North Broad Street

Room 401, Old Medical School

Philadelphia, PA 19140

DATE OF BIRTH: October 26, 1947 7:08 PM EST

PLACE OF BIRTH: Philadelphia, PA

MARITAL STATUS: Married to Robert Grenetz October 22, 1995.

CHILDREN: Jessica Gwen Scott, born August 11, 1971 2:22 PM EDT Fox Chase, PA

EDUCATION:

1965-1967 Temple University, Pre-Pharmacy Curriculum (no degree)

1972-1976 University of Pennsylvania, Biology Major, part-time (no degree)

WORK EXPERIENCE:

1967-1968 Technical Assistant (Dr. Leonard H. Cohen)

Institute for Cancer Research, Fox Chase, PA 19111

1968-1971 Technician (Dr. Leonard H. Cohen)

Institute for Cancer Research, Fox Chase, PA 19111

1973-1974 Research Technician (Dr. Joseph Bryan)

University of Pennsylvania, Philadelphia, PA 19104

1974-1978 Research Assistant (Dr. Robert W. Colman)

University of Pennsylvania, Philadelphia, PA 19104

1978-1980 Research Assistant (Dr. Robert W. Colman)

Thrombosis Research Center, Temple University School of Medicine,

Philadelphia, PA 19140

1980-1999 Research Associate (Dr. Robert W. Colman)

The Sol Sherry Thrombosis Research Center

Temple University School of Medicine

Philadelphia, PA 19140

ADMINISTRATIVE APPOINTMENTS:

1985-1999 Laboratory Manager, The Sol Sherry Thrombosis Research Center

TEACHING EXPERIENCE:

1983-1984 Temple University Hemostasis Update

Assisted in conducting a workshop on chromogenic substrates

1985-1986 Temple University Hemostasis Update

Organized, designed and conducted a workshop on chromogenic substrates

1985-1987 Wrote several teaching manuals for Helena Laboratories on the theory and application of chromogenic substrates

1987 Invited Speaker, Medical Technology Society of North Carolina

Lectured on the use of chromogenic substrates in the hemostasis laboratory

May 1988 Invited Speaker, FASEB. Conducted a tutorial session for Falcon Plastics on the determination of enzyme kinetics in microplates.

1988 Wrote an article for Falcon Plastics on the determinations of enzyme kinetics in microplates.

1989 Temple University Hemostasis Update

Conducted a workshop on chromogenic substrates

1990 Temple University Hemostasis Update

Lectured on the use of chromogenic substrates in the hemostasis laboratory

1990 Invited Speaker, Vroman Symposium, Gouda, Netherlands

1992 Lectured for Kabi/Pharmacia on sepsis

1994 Invited speaker for CME course sponsored by the West Virginia University School Of Medicine

AWARDS AND HONORS:

1983 Erwin Margulies Award for Excellence in Thrombosis Research (2nd place)

1989 Who's Who in America

1996 Who's On-line

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

1975 Kinin Club (FASEB)

1980 American Physiological Society (FASEB)

1981 American Association for the Advancement of Science

1981 New York Academy of Sciences

1983 International Society of Thrombosis and Haemostasis

1984 National Coalition for Science and Technology

1984 Member, Subcommittee on Contact Factors, International Committee on Thrombosis and Haemostasis

1985 Member, Subcommittee on Artificial Surfaces, International Committee on Thrombosis and Haemostasis

1986-1988 Chairperson, Women's Caucus (American Physiological Society)

1986 American Heart Association - Thrombosis Council

1987 Society for Experimental Biology and Medicine

1989 Scientists Center for Animal Welfare

1990 American Society for Investigational Pathology

RESEARCH REVIEW COMMITTEES:

1983 Grant reviewer for National Science Foundation

REVIEWER FOR THE FOLLOWING JOURNALS:

Thrombosis and Haemostasis, Blood, Journal Of Biomaterial Sciences, Infection and Immunity

PATENTS:

1989 High molecular weight kininogen assay #4,882,272 (Cheryl F. Scott and Robert W. Colman)

1998 Solid Phase Immunoassay (Cheryl Faye Schwartz) #5,789,261

CONSULTANTSHIPS:

1985-1987 Kabi Vitrum and its US distributor, Helena Laboratories

1988 Falcon Plastics

1991 Seradyn, Inc.

1992 Xenopore Corporation

2004 Levpharma

BUSINESS EXPERIENCE

1996-present CEO and Director of Research for ImmunoDiagnostic Experimental Associates, Inc. (IDEA). Responsible for developing new technology and overseeing the technical staff. Also responsible for making most of the decisions regarding policy for the company

1996-present Chairman and CEO of BenSalem Health Innovations, Inc. Responsible for making all decisions regarding policy of the corporation.

1989-present Owner of BenSalem Naturals (a subsidiary of BenSalem Health Innovations, Inc. see below). Responsible for making all decisions regarding policy for the company. Also responsible for ordering supplies, shipping orders to customers, and answering customers' questions.

COMPUTER and INTERNET RELATED ACTIVITIES

1994-1995 Avery Dennison. Beta tester for Label Pro and Label Assistant software

1995 Microsoft Corporation. Windows 95 Preview Program

1995-1996 Microsoft Corporation. Beta tester for the Microsoft Network, versions 1.0, 1.05, 1.2 and 1.3.

1995-1996 Designed and constructed BenSalem Naturals Web site

1996 Designed and constructed Web site for the Sol Sherry Thrombosis Research Center

1996 Webmaster for the Sol Sherry Thrombosis Research Center

1996 Designed and constructed Web site for the Philadelphia Astrological Society

1996 Designed and constructed Web site for the ASTEROIDS/Jacob Schwartz, Ph.D.

1996 Attained Level 2 web developer status from the Microsoft Sitebuilder Network

1996 Won a $1000 shopping spree from Microsoft for site design/authoring of BenSalem Naturals

1997 Won Editor's Choice Award from LookSmart for site design/content of the Sol Sherry Thrombosis Research Center

1997 Microsoft's Active Channel Guide for BenSalem Naturals (Lifestyle & Travel section)

1998 Designed and constructed website for the 1999 Gordon Research Conference on Kallikreins and Kinins

1998 Microsoft Corporation. Windows 98 Preview Program

1998 Microsoft Corporation. Office 2000 Preview Program

1998 Designed and constructed website for BioTherapies, Inc.

SCIENTIFIC PUBLICATIONS:

	1. Lin Y-C, Scott CF, Cohen LH. Multiple forms of fumarase of pig heart. Arch Biochem Biophys 144:741-748, 1971
	2. Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP: Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 56:1650-1662, 1975
	3. Meier HL, Scott CF, Mandle R Jr., Webster ME, Pierce JV, Colman RW, Kaplan AP: Requirements for contact activation of human Hageman factor. Ann NY Acad. Sci 283:93-103, 1977
	4. Liu CY, Scott CF, Bagdasarian A, Pierce JV, Kaplan AP, Colman RW: Potentiation of the function of Hageman factor fragments by high molecular weight kininogen. J Clin Invest 60:7-17, 1977
	5. Colman RW, Edelman R, Scott CF, Gilman RH: Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest 61:287-296, 1978
	6. Colman RW, Scott CF, Shames PV, Dayal V, Liu CY, Kirby EP: Prekallikrein activation by Hageman factor: potentiation by proteins in the absence of high molecular weight kininogen. Trans Assoc. Am Physicians 92:208-217, 1979
	7. Scott CF, Liu CY, Colman RW: Human plasma prekallikrein: a rapid high-yield method for purification. Eur J Biochem 100:77-83, 1979
	8. Scott CF, Colman RW: Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J Clin Invest 65:413-421, 1980
	9. Scott CF, Kirby EP, Schick PK, Colman RW: Effect of surfaces on fluid-phase prekallikrein activation. Blood 57:553-560, 1981
	10. Schapira M, Scott CF, Colman RW: Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry 20:2738-2743, 1981
	11. Colman RW, Schapira M, Scott CF. Regulation of the formation and inhibition of human plasma kallikrein. Ann NY Acad. Sci 370:261-270, 1981
	12. Schapira M, Scott CF, Colman RW: High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitors. Trans Assoc. Am Physicians 94:190-197, 1981
	13. Schapira M, Scott CF, James A, Silver LD, Kueppers F, James HL, Colman RW: High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochemistry 21:567-572, 1982
	14. Scott CF, Schapira M, James HL, Cohen AB, Colman RW: Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest 69:844-852, 1982
	15. Schapira M, Scott CF, Colman RW: Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 69:462-468, 1982
	16. Schapira M, Despland E, Scott CF, Boxer LA, Colman RW: Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 69:1199-1202, 1982
	17. Schapira M, Silver LD, Scott CF, Colman RW: New and rapid functional assay for C1 inhibitor in human plasma. Blood 59:719-724, 1982
	18. Scott CF, Schapira M, Colman RW: Effect of heparin on the inactivation rate of human factor XIa by antithrombin-III. Blood 60:940-947, 1982
	19. Wachtfogel YT, Kucich U, James HL, Scott CF, Schapira M, Zimmerman M, Cohen AB, Colman RW: Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 72:1672-1677, 1983
	20. Schapira M, James A, Scott CF, Kueppers F, James HL, Cohen AB, Colman RW: Role of high molecular weight kininogen in modulating the inactivation of human plasma kallikrein by plasma protease inhibitors. Adv. Exp. Med Biol. 156:131-141, 1983
	21. Schapira M, Scott CF, Boxer LA, Colman RW: Activation of human polymorphonuclear leukocytes by purified human plasma kallikrein. Adv. Exp. Med Biol. 156:747-753, 1983
	22. Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis LJ, Jr., Curd JG, Colman RW: Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl. J Med 308:1050-1053, 1983
	23. Scott CF, Sinha D, Seaman FS, Walsh PN, Colman RW: Amidolytic assay of human factor XI in plasma: comparison with a coagulant assay and a new rapid radioimmunoassay. Blood 63:42-50, 1984
	24. Scott CF, Silver LD, Schapira M, Colman RW: Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. J Clin Invest 73:954-962, 1984
	25. Colman RW, Silver LD, Purdon AD, Chang JJ, Scott CF: Regulation of the coagulant activity and surface binding of high molecular weight kininogen. Trans Assoc. Am Physicians 97:113-123, 1984
	26. Colman RW, Wachtfogel YT, Kucich U, Weinbaum G, Hahn S, Pixley RA, Scott CF, de Agostini A, Burger D, Schapira M: Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. Blood 65:311-318, 1985
	27. Scott CF, Silver LD, Purdon AD, Colman RW: Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol. Chem. 260:10856-10863, 1985
	28. Chang JJ, Scott CF, Colman RW: Role of arginine residues in the coagulant activity of high molecular weight kininogen. Blood 67:805-810, 1986
	29. Scott CF, Carrell RW, Glaser CB, Kueppers F, Lewis JH, Colman RW: Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. J Clin Invest 77:631-634, 1986
	30. Scott CF, Carrell RW, Glaser CB, Lewis JH, Colman RW: Alpha 1-antitrypsin-Pittsburgh: a potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. Trans Assoc. Am Physicians 98:344-351, 1985
	31. Schmaier AH, Bradford H, Silver LD, Farber A, Scott CF, Schutsky D, Colman RW: High molecular weight kininogen is an inhibitor of platelet calpain. J Clin Invest 77:1565-1573, 1986
	32. Scott CF, Mentzer RL, Budzynski AZ, Colman RW: Human factor XIa cleaves fibrinogen: effects on structure and function. Arch Biochem Biophys 249:480-488, 1986
	33. Scott CF, Wenzel HR, Tschesche HR, Colman RW: Kinetics of inhibition of human plasma kallikrein by a site-specific modified inhibitor Arg15-aprotinin: evaluation using a microplate system and comparison with other proteases. Blood 69:1431-1436, 1987
	34. Scott CF. Determination of antithrombin III (AT III) using the Coatest" Antithrombin Kit and a microplate system. Ann NY Acad. Sci 485:443-444, 1986
	35. Colman RW, Scott CF, Schmaier AH, Wachtfogel YT, Pixley RA, Edmunds LH, Jr.: Initiation of blood coagulation at artificial surfaces. Ann N Y Acad. Sci 516:253-267, 1987
	36. Scott CF. Appropriate animal models for blood-artificial surface research. Ann NY Acad. Sci 516:636-637, 1987
	37. De La Cadena RA, Scott CF, Colman RW: Evaluation of a microassay for human plasma prekallikrein. J Lab Clin Med 109:601-607, 1987
	38. Scott CF, Pixley RA, Colman RW: A new assay for high molecular weight kininogen in human plasma using a chromogenic substrate. Thromb Res. 48:685-700, 1987
	39. Colman RW, Flores DN, DeLa Cadena RA, Scott CF, Cousens L, Barr PJ, Hoffman IB, Kueppers F, Fisher D, Idell S: Recombinant alpha 1-antitrypsin Pittsburgh attenuates experimental gram-negative septicemia. Am J Pathol 130:418-426, 1988
	40. Brash JL, Scott CF, ten Hove P, Wojciechowski P, Colman RW: Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. Blood 71:932-939, 1988
	41. Colman RW, Scott CF, Pixley RA, De La Cadena RA: Effect of heparin on the inhibition of the contact system enzymes. Ann N Y Acad. Sci 556:95-103, 1989
	42. Scott CF, Colman RW: A simple and accurate microplate assay for the determination of factor XI in plasma. J Lab Clin Med 111:708-714, 1988
	43. Carvalho AC, DeMarinis S, Scott CF, Silver LD, Schmaier AH, Colman RW: Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J Lab Clin Med 112:270-277, 1988
	44. Scott CF, Colman RW: Factors influencing the acceleration of human factor XIa inactivation by antithrombin III. Blood 73:1873-1879, 1989
	45. Tschesche H, Beckmann J, Mehlich A, Feldmann A, Wenzel HR, Scott CF, Colman RW: Semisynthetic arginine-15-aprotinin, an improved inhibitor for human plasma kallikrein. Adv. Exp. Med Biol. 247B:15-21, 1989
	46. Scott CF. Mechanism of the participation of the contact system in the Vroman effect: Review and summary. J Biomater. Sci, Polymer Ed 2:173-181, 1991
	47. Scott CF, Colman RW: Sensitive antigenic determinations of high molecular weight kininogen performed by covalent coupling of capture antibody. J Lab Clin Med 119:77-86, 1992
	48. Scott CF, Colman RW: Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate. Proc Natl. Acad. Sci U S A 89:11189-11193, 1992
	49. Scott CF, Whitaker EJ, Hammond BF, Colman RW: Purification and characterization of a potent 70 kDa thiol lysyl-proteinase (lys-gingivain) from P. gingivalis that cleaves kininogens and fibrinogen. J Biol. Chem. 268:7935-7942, 1993.
	50. Cheung PP, Kunapuli SP, Scott CF, Wachtfogel YT, Colman RW. Genetic basis of total kininogen deficiency in Williams' Trait. J. Biol. Chem. 268:23361-23365,1993.
	51. Pixley RA, Zellis S, Bankes P, DeLa Cadena RA, Page JD, Scott CF, Kappelmayer J, Wyshock EG, Kelly JJ Colman RW. The prognostic value of assessing contact system activation and Factor V in Systemic Inflammatory Response Syndrome. Crit. Care Med. 23:41-51, 1994.
	52. Scott, CF, Shull, B, Werner M�ller-Esterl, W, Colman, RW. Rapid Direct Determination Of Low and High Molecular Weight Kininogen In Human Plasma By Particle Concentration Fluorescence Immunoassay (PCFIA). Thromb. Haemost. 77: 109-118, 1997.
	53. Scott CF, Brandwein H, Whitbread J, Colman RW. Lack of Clinically Significant Contact System Activation During Platelet Concentrate Filtration by Leukocyte Removal Filters. Blood (in press), 1998. Colman RW, Scott CF, Brandwein H, Whitbread J. More on kininogen measurements in platelet concentrates that are white cell (WBC) reduced with WBC-reduction filters [letter; comment] Transfusion: 36(10):939-41, 1996.
	54. Scott CF, Brandwein H, Whitbread J, Colman RW. Lack of Clinically Significant Contact Activation During Platelet Concentrate Filtration by Leukocyte Removal Filters. Blood: 92 (2) 616-22, 1998.
	55. Colman RW, Scott CF. Hypotensive reactions during transfusion: is bradykinin the culprit? [letter; comment] Transfusion 39(1):107-9,1999
	56. Cugno M, Scott CF, Salerno F, Lorenzano E, M�ller-Esterl W, Agostoni A Colman RW. Parallel reduction of plasma levels of high and low molecular weight kininogen in patients with cirrhosis. Thromb. Haemost. 82,1428-32, 1999.